“Longtime believers in Ambrx Biopharma Inc. are being rewarded with juicy returns as Johnson & Johnson’s buyout offer values the biotech stock at more than 6,700% of its all-time low. Johnson & Johnson agreed to acquire Ambrx for $28 per… Continue Reading…